nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—migraine—Prednisone—prostate cancer	0.451	1	CpDpCtD
Ergotamine—CYP3A4—prostate cancer	0.0759	1	CbGaD
Ergotamine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0263	0.0885	CbGbCtD
Ergotamine—CYP1A2—Flutamide—prostate cancer	0.0218	0.0735	CbGbCtD
Ergotamine—ABCB1—Estramustine—prostate cancer	0.0214	0.0721	CbGbCtD
Ergotamine—CYP1A2—Estrone—prostate cancer	0.0158	0.0531	CbGbCtD
Ergotamine—ADRA1B—vas deferens—prostate cancer	0.0151	0.466	CbGeAlD
Ergotamine—ABCB1—Cabazitaxel—prostate cancer	0.0141	0.0475	CbGbCtD
Ergotamine—CYP3A4—Bicalutamide—prostate cancer	0.0138	0.0465	CbGbCtD
Ergotamine—ABCB1—Estrone—prostate cancer	0.0138	0.0465	CbGbCtD
Ergotamine—CYP3A4—Estramustine—prostate cancer	0.0128	0.0432	CbGbCtD
Ergotamine—ABCB1—Ethinyl Estradiol—prostate cancer	0.0123	0.0414	CbGbCtD
Ergotamine—CYP3A4—Flutamide—prostate cancer	0.0114	0.0385	CbGbCtD
Ergotamine—CYP3A4—Abiraterone—prostate cancer	0.0114	0.0385	CbGbCtD
Ergotamine—CYP1A2—Conjugated Estrogens—prostate cancer	0.0103	0.0348	CbGbCtD
Ergotamine—CYP1A2—Estradiol—prostate cancer	0.00906	0.0305	CbGbCtD
Ergotamine—ABCB1—Conjugated Estrogens—prostate cancer	0.00902	0.0304	CbGbCtD
Ergotamine—CYP3A4—Cabazitaxel—prostate cancer	0.00846	0.0285	CbGbCtD
Ergotamine—CYP3A4—Estrone—prostate cancer	0.00826	0.0278	CbGbCtD
Ergotamine—ABCB1—Mitoxantrone—prostate cancer	0.0082	0.0276	CbGbCtD
Ergotamine—ABCB1—Estradiol—prostate cancer	0.00792	0.0267	CbGbCtD
Ergotamine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00737	0.0248	CbGbCtD
Ergotamine—ABCB1—Prednisone—prostate cancer	0.00681	0.0229	CbGbCtD
Ergotamine—CYP1A2—Etoposide—prostate cancer	0.00592	0.0199	CbGbCtD
Ergotamine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00541	0.0182	CbGbCtD
Ergotamine—ABCB1—Etoposide—prostate cancer	0.00517	0.0174	CbGbCtD
Ergotamine—CYP3A4—Mitoxantrone—prostate cancer	0.00491	0.0166	CbGbCtD
Ergotamine—CYP3A4—Estradiol—prostate cancer	0.00475	0.016	CbGbCtD
Ergotamine—ABCB1—Docetaxel—prostate cancer	0.00473	0.0159	CbGbCtD
Ergotamine—CYP3A4—Prednisone—prostate cancer	0.00408	0.0137	CbGbCtD
Ergotamine—ABCB1—Doxorubicin—prostate cancer	0.00353	0.0119	CbGbCtD
Ergotamine—CYP3A4—Etoposide—prostate cancer	0.0031	0.0104	CbGbCtD
Ergotamine—CYP3A4—Docetaxel—prostate cancer	0.00284	0.00955	CbGbCtD
Ergotamine—CYP3A4—Doxorubicin—prostate cancer	0.00211	0.00712	CbGbCtD
Ergotamine—CYP1A2—urine—prostate cancer	0.00174	0.0539	CbGeAlD
Ergotamine—Ischaemia—Mitoxantrone—prostate cancer	0.00163	0.0301	CcSEcCtD
Ergotamine—Localised oedema—Capecitabine—prostate cancer	0.00158	0.029	CcSEcCtD
Ergotamine—HTR2A—urine—prostate cancer	0.00136	0.0421	CbGeAlD
Ergotamine—ADRA1D—prostate gland—prostate cancer	0.00132	0.0407	CbGeAlD
Ergotamine—CYP3A4—urine—prostate cancer	0.00126	0.039	CbGeAlD
Ergotamine—Cyanosis—Conjugated Estrogens—prostate cancer	0.00113	0.0208	CcSEcCtD
Ergotamine—ADRA1D—epithelium—prostate cancer	0.000967	0.0299	CbGeAlD
Ergotamine—ADRA1B—renal system—prostate cancer	0.000917	0.0284	CbGeAlD
Ergotamine—ADRA1D—urethra—prostate cancer	0.000881	0.0273	CbGeAlD
Ergotamine—Peripheral coldness—Capecitabine—prostate cancer	0.000838	0.0154	CcSEcCtD
Ergotamine—Hypoaesthesia—Nilutamide—prostate cancer	0.000803	0.0148	CcSEcCtD
Ergotamine—Numbness—Estradiol—prostate cancer	0.000772	0.0142	CcSEcCtD
Ergotamine—ADRA1A—prostate gland—prostate cancer	0.000756	0.0234	CbGeAlD
Ergotamine—Sensory loss—Estradiol—prostate cancer	0.000739	0.0136	CcSEcCtD
Ergotamine—Hypoaesthesia—Degarelix—prostate cancer	0.000717	0.0132	CcSEcCtD
Ergotamine—Cyanosis—Etoposide—prostate cancer	0.000701	0.0129	CcSEcCtD
Ergotamine—Hypoaesthesia—Cabazitaxel—prostate cancer	0.000676	0.0124	CcSEcCtD
Ergotamine—Hypertension—Abiraterone—prostate cancer	0.000664	0.0122	CcSEcCtD
Ergotamine—Myalgia—Abiraterone—prostate cancer	0.000655	0.012	CcSEcCtD
Ergotamine—Hypertension—Nilutamide—prostate cancer	0.000607	0.0112	CcSEcCtD
Ergotamine—Hypertension—Flutamide—prostate cancer	0.000604	0.0111	CcSEcCtD
Ergotamine—Numbness—Etoposide—prostate cancer	0.000598	0.011	CcSEcCtD
Ergotamine—Bradycardia—Bicalutamide—prostate cancer	0.000593	0.0109	CcSEcCtD
Ergotamine—ADRA2A—prostate gland—prostate cancer	0.000575	0.0178	CbGeAlD
Ergotamine—Sensory loss—Etoposide—prostate cancer	0.000572	0.0105	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Abiraterone—prostate cancer	0.000572	0.0105	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Estrone—prostate cancer	0.000562	0.0103	CcSEcCtD
Ergotamine—HTR1A—renal system—prostate cancer	0.000559	0.0173	CbGeAlD
Ergotamine—ADRA1A—epithelium—prostate cancer	0.000555	0.0172	CbGeAlD
Ergotamine—Hypertension—Degarelix—prostate cancer	0.000542	0.00997	CcSEcCtD
Ergotamine—Vertigo—Cabazitaxel—prostate cancer	0.000531	0.00977	CcSEcCtD
Ergotamine—Pain—Estrone—prostate cancer	0.000528	0.00971	CcSEcCtD
Ergotamine—ADRA1A—renal system—prostate cancer	0.000515	0.0159	CbGeAlD
Ergotamine—Paraesthesia—Nilutamide—prostate cancer	0.000515	0.00947	CcSEcCtD
Ergotamine—Hypertension—Cabazitaxel—prostate cancer	0.00051	0.00939	CcSEcCtD
Ergotamine—Myalgia—Cabazitaxel—prostate cancer	0.000503	0.00926	CcSEcCtD
Ergotamine—Pain—Nilutamide—prostate cancer	0.00049	0.00902	CcSEcCtD
Ergotamine—Hypoaesthesia—Ethinyl Estradiol—prostate cancer	0.00049	0.00901	CcSEcCtD
Ergotamine—ADRA2A—seminal vesicle—prostate cancer	0.000486	0.015	CbGeAlD
Ergotamine—Tachycardia—Cabazitaxel—prostate cancer	0.000471	0.00866	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Degarelix—prostate cancer	0.000467	0.00858	CcSEcCtD
Ergotamine—Pain—Estradiol valerate/Dienogest—prostate cancer	0.000461	0.00847	CcSEcCtD
Ergotamine—Pruritus—Estramustine—prostate cancer	0.000457	0.00841	CcSEcCtD
Ergotamine—Asthenia—Abiraterone—prostate cancer	0.00045	0.00828	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Cabazitaxel—prostate cancer	0.00044	0.00809	CcSEcCtD
Ergotamine—Pain—Degarelix—prostate cancer	0.000438	0.00806	CcSEcCtD
Ergotamine—Hypertension—Bicalutamide—prostate cancer	0.000438	0.00805	CcSEcCtD
Ergotamine—Pruritus—Estrone—prostate cancer	0.000437	0.00803	CcSEcCtD
Ergotamine—Paraesthesia—Cabazitaxel—prostate cancer	0.000433	0.00797	CcSEcCtD
Ergotamine—Myalgia—Bicalutamide—prostate cancer	0.000432	0.00794	CcSEcCtD
Ergotamine—CYP1A2—renal system—prostate cancer	0.000426	0.0132	CbGeAlD
Ergotamine—Pain—Cabazitaxel—prostate cancer	0.000413	0.00759	CcSEcCtD
Ergotamine—Asthenia—Nilutamide—prostate cancer	0.000411	0.00757	CcSEcCtD
Ergotamine—Vomiting—Estramustine—prostate cancer	0.000411	0.00756	CcSEcCtD
Ergotamine—Asthenia—Flutamide—prostate cancer	0.00041	0.00753	CcSEcCtD
Ergotamine—Pruritus—Nilutamide—prostate cancer	0.000406	0.00746	CcSEcCtD
Ergotamine—Pruritus—Flutamide—prostate cancer	0.000404	0.00743	CcSEcCtD
Ergotamine—Hypoaesthesia—Conjugated Estrogens—prostate cancer	0.000399	0.00735	CcSEcCtD
Ergotamine—Vomiting—Abiraterone—prostate cancer	0.000399	0.00734	CcSEcCtD
Ergotamine—Vomiting—Estrone—prostate cancer	0.000393	0.00722	CcSEcCtD
Ergotamine—Asthenia—Estradiol valerate/Dienogest—prostate cancer	0.000387	0.00711	CcSEcCtD
Ergotamine—ADRA2A—urethra—prostate cancer	0.000385	0.0119	CbGeAlD
Ergotamine—Nausea—Estramustine—prostate cancer	0.000384	0.00706	CcSEcCtD
Ergotamine—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.000381	0.00701	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Bicalutamide—prostate cancer	0.000377	0.00694	CcSEcCtD
Ergotamine—Paraesthesia—Bicalutamide—prostate cancer	0.000372	0.00684	CcSEcCtD
Ergotamine—Asthenia—Degarelix—prostate cancer	0.000368	0.00676	CcSEcCtD
Ergotamine—Nausea—Estrone—prostate cancer	0.000367	0.00674	CcSEcCtD
Ergotamine—Vomiting—Nilutamide—prostate cancer	0.000365	0.00671	CcSEcCtD
Ergotamine—Vomiting—Flutamide—prostate cancer	0.000363	0.00668	CcSEcCtD
Ergotamine—Pruritus—Degarelix—prostate cancer	0.000362	0.00666	CcSEcCtD
Ergotamine—HTR2A—epithelium—prostate cancer	0.000359	0.0111	CbGeAlD
Ergotamine—SLC6A2—testis—prostate cancer	0.000358	0.0111	CbGeAlD
Ergotamine—Pain—Bicalutamide—prostate cancer	0.000354	0.00651	CcSEcCtD
Ergotamine—Asthenia—Cabazitaxel—prostate cancer	0.000346	0.00637	CcSEcCtD
Ergotamine—Ergoloid mesylate—CYP3A4—prostate cancer	0.000344	0.26	CrCbGaD
Ergotamine—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.000343	0.0063	CcSEcCtD
Ergotamine—Nausea—Nilutamide—prostate cancer	0.000341	0.00626	CcSEcCtD
Ergotamine—Nausea—Flutamide—prostate cancer	0.000339	0.00624	CcSEcCtD
Ergotamine—HTR2A—renal system—prostate cancer	0.000333	0.0103	CbGeAlD
Ergotamine—DRD2—testis—prostate cancer	0.000326	0.0101	CbGeAlD
Ergotamine—Vomiting—Degarelix—prostate cancer	0.000326	0.00599	CcSEcCtD
Ergotamine—ABCB1—prostate gland—prostate cancer	0.00032	0.00991	CbGeAlD
Ergotamine—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.00032	0.00589	CcSEcCtD
Ergotamine—Hypoaesthesia—Estradiol—prostate cancer	0.00032	0.00588	CcSEcCtD
Ergotamine—Vertigo—Conjugated Estrogens—prostate cancer	0.000314	0.00577	CcSEcCtD
Ergotamine—CYP3A4—renal system—prostate cancer	0.000308	0.00954	CbGeAlD
Ergotamine—Vomiting—Cabazitaxel—prostate cancer	0.000307	0.00564	CcSEcCtD
Ergotamine—Bradycardia—Mitoxantrone—prostate cancer	0.000305	0.00561	CcSEcCtD
Ergotamine—Hypertension—Goserelin—prostate cancer	0.000305	0.0056	CcSEcCtD
Ergotamine—Nausea—Degarelix—prostate cancer	0.000304	0.0056	CcSEcCtD
Ergotamine—Myalgia—Goserelin—prostate cancer	0.0003	0.00552	CcSEcCtD
Ergotamine—Myalgia—Conjugated Estrogens—prostate cancer	0.000298	0.00547	CcSEcCtD
Ergotamine—Asthenia—Bicalutamide—prostate cancer	0.000297	0.00546	CcSEcCtD
Ergotamine—Pruritus—Bicalutamide—prostate cancer	0.000293	0.00539	CcSEcCtD
Ergotamine—HTR2B—lymph node—prostate cancer	0.000292	0.00904	CbGeAlD
Ergotamine—Nausea—Cabazitaxel—prostate cancer	0.000287	0.00527	CcSEcCtD
Ergotamine—Tachycardia—Goserelin—prostate cancer	0.000281	0.00517	CcSEcCtD
Ergotamine—Tachycardia—Conjugated Estrogens—prostate cancer	0.000278	0.00512	CcSEcCtD
Ergotamine—ABCB1—seminal vesicle—prostate cancer	0.000271	0.00838	CbGeAlD
Ergotamine—Vomiting—Bicalutamide—prostate cancer	0.000263	0.00484	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Goserelin—prostate cancer	0.000262	0.00482	CcSEcCtD
Ergotamine—Dihydroergotamine—CYP3A4—prostate cancer	0.00026	0.197	CrCbGaD
Ergotamine—Musculoskeletal discomfort—Conjugated Estrogens—prostate cancer	0.00026	0.00478	CcSEcCtD
Ergotamine—SLC6A2—lymph node—prostate cancer	0.00026	0.00803	CbGeAlD
Ergotamine—Paraesthesia—Goserelin—prostate cancer	0.000259	0.00476	CcSEcCtD
Ergotamine—Paraesthesia—Conjugated Estrogens—prostate cancer	0.000256	0.00471	CcSEcCtD
Ergotamine—ADRA2A—testis—prostate cancer	0.000253	0.00783	CbGeAlD
Ergotamine—Vertigo—Estradiol—prostate cancer	0.000251	0.00462	CcSEcCtD
Ergotamine—Asthenia—Ethinyl Estradiol—prostate cancer	0.000251	0.00462	CcSEcCtD
Ergotamine—Hypoaesthesia—Etoposide—prostate cancer	0.000248	0.00456	CcSEcCtD
Ergotamine—Pruritus—Ethinyl Estradiol—prostate cancer	0.000248	0.00455	CcSEcCtD
Ergotamine—Pain—Goserelin—prostate cancer	0.000246	0.00453	CcSEcCtD
Ergotamine—Nausea—Bicalutamide—prostate cancer	0.000246	0.00452	CcSEcCtD
Ergotamine—Pain—Conjugated Estrogens—prostate cancer	0.000244	0.00449	CcSEcCtD
Ergotamine—Hypertension—Estradiol—prostate cancer	0.000241	0.00444	CcSEcCtD
Ergotamine—Ergonovine—CYP3A4—prostate cancer	0.000238	0.181	CrCbGaD
Ergotamine—Myalgia—Estradiol—prostate cancer	0.000238	0.00438	CcSEcCtD
Ergotamine—ABCB1—epithelium—prostate cancer	0.000235	0.00728	CbGeAlD
Ergotamine—Hypertension—Mitoxantrone—prostate cancer	0.000225	0.00414	CcSEcCtD
Ergotamine—Tachycardia—Estradiol—prostate cancer	0.000223	0.0041	CcSEcCtD
Ergotamine—Vomiting—Ethinyl Estradiol—prostate cancer	0.000222	0.00409	CcSEcCtD
Ergotamine—Myalgia—Mitoxantrone—prostate cancer	0.000222	0.00408	CcSEcCtD
Ergotamine—ABCB1—renal system—prostate cancer	0.000218	0.00675	CbGeAlD
Ergotamine—HTR2A—testis—prostate cancer	0.000215	0.00666	CbGeAlD
Ergotamine—ABCB1—urethra—prostate cancer	0.000214	0.00663	CbGeAlD
Ergotamine—Methylergometrine—CYP3A4—prostate cancer	0.000208	0.158	CrCbGaD
Ergotamine—Musculoskeletal discomfort—Estradiol—prostate cancer	0.000208	0.00382	CcSEcCtD
Ergotamine—Nausea—Ethinyl Estradiol—prostate cancer	0.000208	0.00382	CcSEcCtD
Ergotamine—Tachycardia—Mitoxantrone—prostate cancer	0.000208	0.00382	CcSEcCtD
Ergotamine—Asthenia—Goserelin—prostate cancer	0.000207	0.0038	CcSEcCtD
Ergotamine—Hypoaesthesia—Docetaxel—prostate cancer	0.000206	0.00379	CcSEcCtD
Ergotamine—Paraesthesia—Estradiol—prostate cancer	0.000205	0.00377	CcSEcCtD
Ergotamine—Asthenia—Conjugated Estrogens—prostate cancer	0.000205	0.00376	CcSEcCtD
Ergotamine—Bradycardia—Capecitabine—prostate cancer	0.000204	0.00375	CcSEcCtD
Ergotamine—Pruritus—Goserelin—prostate cancer	0.000204	0.00375	CcSEcCtD
Ergotamine—Pruritus—Conjugated Estrogens—prostate cancer	0.000202	0.00371	CcSEcCtD
Ergotamine—Hypoaesthesia—Capecitabine—prostate cancer	0.000199	0.00367	CcSEcCtD
Ergotamine—Pain—Estradiol—prostate cancer	0.000195	0.00359	CcSEcCtD
Ergotamine—Vertigo—Etoposide—prostate cancer	0.000195	0.00358	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000194	0.00356	CcSEcCtD
Ergotamine—Paraesthesia—Mitoxantrone—prostate cancer	0.000191	0.00351	CcSEcCtD
Ergotamine—Hypertension—Etoposide—prostate cancer	0.000187	0.00344	CcSEcCtD
Ergotamine—ADRA2A—lymph node—prostate cancer	0.000184	0.00568	CbGeAlD
Ergotamine—Vomiting—Goserelin—prostate cancer	0.000183	0.00337	CcSEcCtD
Ergotamine—Pain—Mitoxantrone—prostate cancer	0.000182	0.00335	CcSEcCtD
Ergotamine—Bradycardia—Prednisone—prostate cancer	0.000182	0.00334	CcSEcCtD
Ergotamine—Vomiting—Conjugated Estrogens—prostate cancer	0.000181	0.00334	CcSEcCtD
Ergotamine—Tachycardia—Etoposide—prostate cancer	0.000173	0.00318	CcSEcCtD
Ergotamine—Nausea—Goserelin—prostate cancer	0.000171	0.00315	CcSEcCtD
Ergotamine—Nausea—Conjugated Estrogens—prostate cancer	0.000169	0.00312	CcSEcCtD
Ergotamine—ABCB1—bone marrow—prostate cancer	0.000165	0.00511	CbGeAlD
Ergotamine—Asthenia—Estradiol—prostate cancer	0.000164	0.00301	CcSEcCtD
Ergotamine—Pruritus—Estradiol—prostate cancer	0.000162	0.00297	CcSEcCtD
Ergotamine—Paraesthesia—Etoposide—prostate cancer	0.000159	0.00292	CcSEcCtD
Ergotamine—Vertigo—Capecitabine—prostate cancer	0.000157	0.00288	CcSEcCtD
Ergotamine—Hypertension—Docetaxel—prostate cancer	0.000156	0.00286	CcSEcCtD
Ergotamine—Myalgia—Docetaxel—prostate cancer	0.000153	0.00282	CcSEcCtD
Ergotamine—Asthenia—Mitoxantrone—prostate cancer	0.000153	0.00281	CcSEcCtD
Ergotamine—Pain—Etoposide—prostate cancer	0.000151	0.00278	CcSEcCtD
Ergotamine—Hypertension—Capecitabine—prostate cancer	0.000151	0.00277	CcSEcCtD
Ergotamine—Myalgia—Capecitabine—prostate cancer	0.000148	0.00273	CcSEcCtD
Ergotamine—Vomiting—Estradiol—prostate cancer	0.000145	0.00267	CcSEcCtD
Ergotamine—Tachycardia—Docetaxel—prostate cancer	0.000144	0.00264	CcSEcCtD
Ergotamine—Bradycardia—Epirubicin—prostate cancer	0.000142	0.00261	CcSEcCtD
Ergotamine—ABCB1—testis—prostate cancer	0.000141	0.00436	CbGeAlD
Ergotamine—Lisuride—CYP3A4—prostate cancer	0.00014	0.106	CrCbGaD
Ergotamine—Vertigo—Prednisone—prostate cancer	0.00014	0.00257	CcSEcCtD
Ergotamine—Tachycardia—Capecitabine—prostate cancer	0.000139	0.00256	CcSEcCtD
Ergotamine—Hypoaesthesia—Epirubicin—prostate cancer	0.000139	0.00255	CcSEcCtD
Ergotamine—Nausea—Estradiol—prostate cancer	0.000136	0.00249	CcSEcCtD
Ergotamine—Vomiting—Mitoxantrone—prostate cancer	0.000135	0.00249	CcSEcCtD
Ergotamine—Hypertension—Prednisone—prostate cancer	0.000134	0.00247	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000134	0.00246	CcSEcCtD
Ergotamine—Myalgia—Prednisone—prostate cancer	0.000132	0.00243	CcSEcCtD
Ergotamine—Paraesthesia—Docetaxel—prostate cancer	0.000132	0.00243	CcSEcCtD
Ergotamine—Bradycardia—Doxorubicin—prostate cancer	0.000131	0.00242	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.00013	0.00239	CcSEcCtD
Ergotamine—Bromocriptine—CYP3A4—prostate cancer	0.000129	0.0981	CrCbGaD
Ergotamine—Hypoaesthesia—Doxorubicin—prostate cancer	0.000129	0.00236	CcSEcCtD
Ergotamine—Paraesthesia—Capecitabine—prostate cancer	0.000128	0.00235	CcSEcCtD
Ergotamine—Asthenia—Etoposide—prostate cancer	0.000127	0.00233	CcSEcCtD
Ergotamine—Nausea—Mitoxantrone—prostate cancer	0.000126	0.00232	CcSEcCtD
Ergotamine—Pain—Docetaxel—prostate cancer	0.000126	0.00231	CcSEcCtD
Ergotamine—Pruritus—Etoposide—prostate cancer	0.000125	0.0023	CcSEcCtD
Ergotamine—Tachycardia—Prednisone—prostate cancer	0.000124	0.00228	CcSEcCtD
Ergotamine—Pain—Capecitabine—prostate cancer	0.000122	0.00224	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000116	0.00212	CcSEcCtD
Ergotamine—Paraesthesia—Prednisone—prostate cancer	0.000114	0.00209	CcSEcCtD
Ergotamine—Vomiting—Etoposide—prostate cancer	0.000112	0.00207	CcSEcCtD
Ergotamine—Vertigo—Epirubicin—prostate cancer	0.000109	0.00201	CcSEcCtD
Ergotamine—Asthenia—Docetaxel—prostate cancer	0.000105	0.00194	CcSEcCtD
Ergotamine—Nausea—Etoposide—prostate cancer	0.000105	0.00193	CcSEcCtD
Ergotamine—Hypertension—Epirubicin—prostate cancer	0.000105	0.00193	CcSEcCtD
Ergotamine—Pruritus—Docetaxel—prostate cancer	0.000104	0.00191	CcSEcCtD
Ergotamine—Myalgia—Epirubicin—prostate cancer	0.000103	0.0019	CcSEcCtD
Ergotamine—ABCB1—lymph node—prostate cancer	0.000102	0.00316	CbGeAlD
Ergotamine—Asthenia—Capecitabine—prostate cancer	0.000102	0.00188	CcSEcCtD
Ergotamine—Vertigo—Doxorubicin—prostate cancer	0.000101	0.00186	CcSEcCtD
Ergotamine—Pruritus—Capecitabine—prostate cancer	0.000101	0.00185	CcSEcCtD
Ergotamine—Hypertension—Doxorubicin—prostate cancer	9.71e-05	0.00179	CcSEcCtD
Ergotamine—Tachycardia—Epirubicin—prostate cancer	9.68e-05	0.00178	CcSEcCtD
Ergotamine—Myalgia—Doxorubicin—prostate cancer	9.57e-05	0.00176	CcSEcCtD
Ergotamine—Vomiting—Docetaxel—prostate cancer	9.35e-05	0.00172	CcSEcCtD
Ergotamine—Asthenia—Prednisone—prostate cancer	9.1e-05	0.00167	CcSEcCtD
Ergotamine—Vomiting—Capecitabine—prostate cancer	9.05e-05	0.00166	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Epirubicin—prostate cancer	9.04e-05	0.00166	CcSEcCtD
Ergotamine—Pruritus—Prednisone—prostate cancer	8.97e-05	0.00165	CcSEcCtD
Ergotamine—Tachycardia—Doxorubicin—prostate cancer	8.96e-05	0.00165	CcSEcCtD
Ergotamine—Paraesthesia—Epirubicin—prostate cancer	8.91e-05	0.00164	CcSEcCtD
Ergotamine—Nausea—Docetaxel—prostate cancer	8.73e-05	0.00161	CcSEcCtD
Ergotamine—Pain—Epirubicin—prostate cancer	8.48e-05	0.00156	CcSEcCtD
Ergotamine—Nausea—Capecitabine—prostate cancer	8.46e-05	0.00156	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	8.36e-05	0.00154	CcSEcCtD
Ergotamine—Paraesthesia—Doxorubicin—prostate cancer	8.24e-05	0.00152	CcSEcCtD
Ergotamine—Vomiting—Prednisone—prostate cancer	8.06e-05	0.00148	CcSEcCtD
Ergotamine—Pain—Doxorubicin—prostate cancer	7.85e-05	0.00144	CcSEcCtD
Ergotamine—Nausea—Prednisone—prostate cancer	7.53e-05	0.00139	CcSEcCtD
Ergotamine—Asthenia—Epirubicin—prostate cancer	7.12e-05	0.00131	CcSEcCtD
Ergotamine—Pruritus—Epirubicin—prostate cancer	7.02e-05	0.00129	CcSEcCtD
Ergotamine—Asthenia—Doxorubicin—prostate cancer	6.58e-05	0.00121	CcSEcCtD
Ergotamine—Pruritus—Doxorubicin—prostate cancer	6.49e-05	0.00119	CcSEcCtD
Ergotamine—Vomiting—Epirubicin—prostate cancer	6.31e-05	0.00116	CcSEcCtD
Ergotamine—Nausea—Epirubicin—prostate cancer	5.89e-05	0.00108	CcSEcCtD
Ergotamine—Vomiting—Doxorubicin—prostate cancer	5.83e-05	0.00107	CcSEcCtD
Ergotamine—Nausea—Doxorubicin—prostate cancer	5.45e-05	0.001	CcSEcCtD
Ergotamine—ADRA1B—Signaling by GPCR—IL6—prostate cancer	1.71e-06	1.94e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MDM2—prostate cancer	1.71e-06	1.94e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MMP9—prostate cancer	1.71e-06	1.94e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EGFR—prostate cancer	1.7e-06	1.93e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	1.7e-06	1.93e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MMP9—prostate cancer	1.7e-06	1.93e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CYP1A1—prostate cancer	1.7e-06	1.93e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PTEN—prostate cancer	1.7e-06	1.93e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	1.7e-06	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—FGF2—prostate cancer	1.7e-06	1.93e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	1.69e-06	1.92e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PTEN—prostate cancer	1.69e-06	1.92e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ERCC2—prostate cancer	1.69e-06	1.91e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	1.69e-06	1.91e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EP300—prostate cancer	1.68e-06	1.9e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GGT1—prostate cancer	1.68e-06	1.9e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCND1—prostate cancer	1.68e-06	1.9e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NOS3—prostate cancer	1.67e-06	1.9e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CG—prostate cancer	1.67e-06	1.89e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	1.66e-06	1.89e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	1.66e-06	1.88e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CXCL8—prostate cancer	1.66e-06	1.88e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—AKT1—prostate cancer	1.66e-06	1.88e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NCOA1—prostate cancer	1.65e-06	1.87e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—AKT1—prostate cancer	1.65e-06	1.87e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CXCL8—prostate cancer	1.63e-06	1.85e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—SRC—prostate cancer	1.63e-06	1.85e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MMP9—prostate cancer	1.63e-06	1.85e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.63e-06	1.85e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—JAK2—prostate cancer	1.63e-06	1.85e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	1.62e-06	1.84e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EP300—prostate cancer	1.62e-06	1.84e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MYC—prostate cancer	1.62e-06	1.84e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1B—prostate cancer	1.62e-06	1.84e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PTEN—prostate cancer	1.62e-06	1.84e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	1.62e-06	1.83e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EP300—prostate cancer	1.61e-06	1.83e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—KRAS—prostate cancer	1.61e-06	1.83e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	1.61e-06	1.82e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—AKT1—prostate cancer	1.6e-06	1.82e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	1.6e-06	1.81e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTEN—prostate cancer	1.6e-06	1.81e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	1.59e-06	1.81e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	1.59e-06	1.81e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	1.59e-06	1.8e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MDM2—prostate cancer	1.59e-06	1.8e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CASP3—prostate cancer	1.59e-06	1.8e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL2—prostate cancer	1.59e-06	1.8e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MTHFR—prostate cancer	1.58e-06	1.8e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EGFR—prostate cancer	1.58e-06	1.8e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—INS—prostate cancer	1.58e-06	1.79e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	1.58e-06	1.79e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL6—prostate cancer	1.58e-06	1.79e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	1.58e-06	1.79e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—SRC—prostate cancer	1.58e-06	1.79e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—STAT3—prostate cancer	1.57e-06	1.79e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	1.57e-06	1.79e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—RXRA—prostate cancer	1.57e-06	1.78e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—SRC—prostate cancer	1.57e-06	1.78e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	1.57e-06	1.78e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CASP3—prostate cancer	1.56e-06	1.77e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	1.56e-06	1.77e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL2—prostate cancer	1.56e-06	1.77e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PPARA—prostate cancer	1.55e-06	1.76e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—prostate cancer	1.55e-06	1.76e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL6—prostate cancer	1.55e-06	1.76e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CREBBP—prostate cancer	1.55e-06	1.75e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCND1—prostate cancer	1.55e-06	1.75e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	1.55e-06	1.75e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	1.54e-06	1.75e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EP300—prostate cancer	1.54e-06	1.75e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—VEGFA—prostate cancer	1.53e-06	1.74e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CTNNB1—prostate cancer	1.53e-06	1.74e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CASP3—prostate cancer	1.53e-06	1.74e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL2—prostate cancer	1.53e-06	1.73e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—VEGFA—prostate cancer	1.53e-06	1.73e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—EP300—prostate cancer	1.52e-06	1.73e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—prostate cancer	1.52e-06	1.73e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCND1—prostate cancer	1.52e-06	1.73e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL6—prostate cancer	1.52e-06	1.72e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—STAT3—prostate cancer	1.52e-06	1.72e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—COMT—prostate cancer	1.51e-06	1.72e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—STAT3—prostate cancer	1.51e-06	1.72e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	1.51e-06	1.71e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTP1—prostate cancer	1.51e-06	1.71e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—SRC—prostate cancer	1.5e-06	1.7e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MMP9—prostate cancer	1.5e-06	1.7e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—KRAS—prostate cancer	1.5e-06	1.7e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1A—prostate cancer	1.5e-06	1.7e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PTEN—prostate cancer	1.49e-06	1.69e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCND1—prostate cancer	1.49e-06	1.69e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	1.48e-06	1.69e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ITPR1—prostate cancer	1.48e-06	1.68e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	1.48e-06	1.68e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MMP9—prostate cancer	1.48e-06	1.68e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	1.47e-06	1.67e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	1.47e-06	1.67e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PTEN—prostate cancer	1.47e-06	1.67e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CD—prostate cancer	1.47e-06	1.66e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MYC—prostate cancer	1.46e-06	1.66e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CAV1—prostate cancer	1.46e-06	1.66e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	1.46e-06	1.66e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	1.46e-06	1.66e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—AKT1—prostate cancer	1.46e-06	1.65e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	1.45e-06	1.65e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—STAT3—prostate cancer	1.45e-06	1.64e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MMP9—prostate cancer	1.45e-06	1.64e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	1.44e-06	1.63e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PTEN—prostate cancer	1.44e-06	1.63e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	1.43e-06	1.63e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—AKT1—prostate cancer	1.43e-06	1.62e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EGFR—prostate cancer	1.43e-06	1.62e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—prostate cancer	1.43e-06	1.62e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL6—prostate cancer	1.42e-06	1.61e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EP300—prostate cancer	1.42e-06	1.61e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	1.42e-06	1.61e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL2—prostate cancer	1.42e-06	1.61e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	1.41e-06	1.6e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MYC—prostate cancer	1.41e-06	1.6e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TGFB1—prostate cancer	1.41e-06	1.6e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MYC—prostate cancer	1.4e-06	1.59e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	1.4e-06	1.59e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TGFB1—prostate cancer	1.4e-06	1.59e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—TYMS—prostate cancer	1.4e-06	1.59e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EP300—prostate cancer	1.4e-06	1.59e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.4e-06	1.58e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL6—prostate cancer	1.39e-06	1.58e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—NOS3—prostate cancer	1.38e-06	1.57e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTM1—prostate cancer	1.38e-06	1.57e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	1.38e-06	1.57e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—SRC—prostate cancer	1.38e-06	1.57e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EGFR—prostate cancer	1.38e-06	1.57e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	1.38e-06	1.56e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EGFR—prostate cancer	1.37e-06	1.56e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EP300—prostate cancer	1.37e-06	1.56e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	1.37e-06	1.55e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SRC—prostate cancer	1.36e-06	1.54e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—LPL—prostate cancer	1.36e-06	1.54e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—KRAS—prostate cancer	1.35e-06	1.53e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—VEGFA—prostate cancer	1.35e-06	1.53e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MYC—prostate cancer	1.34e-06	1.53e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	1.34e-06	1.52e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	1.34e-06	1.52e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	1.34e-06	1.52e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	1.34e-06	1.52e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—STAT3—prostate cancer	1.33e-06	1.51e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SRC—prostate cancer	1.33e-06	1.51e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.33e-06	1.51e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—prostate cancer	1.33e-06	1.51e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—VEGFA—prostate cancer	1.33e-06	1.5e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EGFR—prostate cancer	1.32e-06	1.49e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—STAT3—prostate cancer	1.31e-06	1.49e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—AKT1—prostate cancer	1.31e-06	1.49e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.31e-06	1.49e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL6—prostate cancer	1.31e-06	1.49e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—KRAS—prostate cancer	1.3e-06	1.48e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	1.3e-06	1.48e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ERCC2—prostate cancer	1.3e-06	1.48e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	1.3e-06	1.47e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—KRAS—prostate cancer	1.3e-06	1.47e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—AKT1—prostate cancer	1.29e-06	1.46e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—STAT3—prostate cancer	1.29e-06	1.46e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CB—prostate cancer	1.28e-06	1.45e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EP300—prostate cancer	1.27e-06	1.45e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—prostate cancer	1.27e-06	1.44e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—INS—prostate cancer	1.26e-06	1.43e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—KRAS—prostate cancer	1.24e-06	1.41e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	1.24e-06	1.41e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MYC—prostate cancer	1.24e-06	1.41e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SRC—prostate cancer	1.24e-06	1.41e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TGFB1—prostate cancer	1.24e-06	1.4e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CREBBP—prostate cancer	1.23e-06	1.4e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MTHFR—prostate cancer	1.22e-06	1.39e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MYC—prostate cancer	1.22e-06	1.38e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL6—prostate cancer	1.22e-06	1.38e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TGFB1—prostate cancer	1.22e-06	1.38e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EGFR—prostate cancer	1.21e-06	1.38e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—AKT1—prostate cancer	1.21e-06	1.37e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	1.21e-06	1.37e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—prostate cancer	1.2e-06	1.36e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPARA—prostate cancer	1.2e-06	1.36e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	1.2e-06	1.36e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MYC—prostate cancer	1.19e-06	1.36e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	1.19e-06	1.36e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EGFR—prostate cancer	1.19e-06	1.35e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	1.19e-06	1.35e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	1.19e-06	1.35e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CD—prostate cancer	1.17e-06	1.33e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EGFR—prostate cancer	1.17e-06	1.33e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—prostate cancer	1.16e-06	1.32e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—prostate cancer	1.15e-06	1.31e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—KRAS—prostate cancer	1.15e-06	1.3e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	1.14e-06	1.3e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CAV1—prostate cancer	1.13e-06	1.28e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—KRAS—prostate cancer	1.13e-06	1.28e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PIK3CA—prostate cancer	1.13e-06	1.28e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—AKT1—prostate cancer	1.12e-06	1.27e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MYC—prostate cancer	1.11e-06	1.26e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	1.11e-06	1.26e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—NOS3—prostate cancer	1.11e-06	1.25e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTEN—prostate cancer	1.1e-06	1.25e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—prostate cancer	1.1e-06	1.25e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—KRAS—prostate cancer	1.1e-06	1.25e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL6—prostate cancer	1.1e-06	1.25e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	1.09e-06	1.23e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL6—prostate cancer	1.06e-06	1.2e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL6—prostate cancer	1.06e-06	1.2e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—EP300—prostate cancer	1.05e-06	1.19e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PIK3CA—prostate cancer	1.05e-06	1.19e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	1.04e-06	1.17e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.03e-06	1.17e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	1.03e-06	1.16e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.02e-06	1.16e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—prostate cancer	1.02e-06	1.16e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—AKT1—prostate cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—prostate cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL6—prostate cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—prostate cancer	1e-06	1.14e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—prostate cancer	9.81e-07	1.11e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—AKT1—prostate cancer	9.79e-07	1.11e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—AKT1—prostate cancer	9.74e-07	1.11e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—INS—prostate cancer	9.73e-07	1.1e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CREBBP—prostate cancer	9.53e-07	1.08e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	9.42e-07	1.07e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—AKT1—prostate cancer	9.32e-07	1.06e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL6—prostate cancer	9.32e-07	1.06e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—AKT1—prostate cancer	9.2e-07	1.04e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL6—prostate cancer	9.17e-07	1.04e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—prostate cancer	9.11e-07	1.03e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CD—prostate cancer	9.03e-07	1.02e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL6—prostate cancer	8.98e-07	1.02e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTEN—prostate cancer	8.82e-07	1e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—AKT1—prostate cancer	8.6e-07	9.75e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NOS3—prostate cancer	8.53e-07	9.68e-06	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—AKT1—prostate cancer	8.46e-07	9.6e-06	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—EP300—prostate cancer	8.41e-07	9.54e-06	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6—prostate cancer	8.34e-07	9.47e-06	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—AKT1—prostate cancer	8.28e-07	9.4e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CB—prostate cancer	7.87e-07	8.93e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—prostate cancer	7.8e-07	8.85e-06	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CA—prostate cancer	7.79e-07	8.84e-06	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	7.7e-07	8.73e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTEN—prostate cancer	6.8e-07	7.72e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—EP300—prostate cancer	6.49e-07	7.36e-06	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—AKT1—prostate cancer	6.36e-07	7.22e-06	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CA—prostate cancer	6.22e-07	7.06e-06	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—AKT1—prostate cancer	5.08e-07	5.76e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CA—prostate cancer	4.8e-07	5.45e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AKT1—prostate cancer	3.92e-07	4.45e-06	CbGpPWpGaD
